Sahar Barjesteh van Waalwijk van Doorn-Khosrovani/LinkedIn
Oct 30, 2024, 12:41
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani: Debates on weight-based dosing of pembrolizumab
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Podcast Host of De Bruggenbouwers, shared on LinkedIn:
“The debates on weight-based dosing of pembrolizumab, which can save money, have led to the publication of a Dutch guideline on de-escalation strategies and off-label use.
Here I give some background, context and share my thoughts on the way forward.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 7, 2025, 19:57
Aug 7, 2025, 19:49
Aug 7, 2025, 19:29
Aug 7, 2025, 19:26